AIM IMMUNOTECH INC.: proceeds from issuing common stock

What this measure means

Cash received from issuing common stock during the period. It is gross of costs only where the filer reports it so, and it does not include noncash issuances.

Exact concept: us-gaap:ProceedsFromIssuanceOfCommonStock. Each value covers an annual-duration reporting interval, shown with both start and end dates. Different units remain separate; no currency conversion or interpolation is applied.

Coverage of this history

Selected reporting periods run from 2009-01-01 to 2021-12-31. The SEC response was captured on 2026-09-20.

This selected history ends more than two years before capture. Do not treat its final value as a current balance or current annual result. More recent filings may use another accounting tag; inspect the filings before drawing conclusions about the company.

Selected filing history

Related financial histories

• AIM IMMUNOTECH INC.: total assets
• AIM IMMUNOTECH INC.: total liabilities
• AIM IMMUNOTECH INC.: stockholders equity
• AIM IMMUNOTECH INC.: cash and cash equivalents
• AIM IMMUNOTECH INC.: net income or loss
• AIM IMMUNOTECH INC.: operating cash flow
• AIM IMMUNOTECH INC.: capital expenditure payments
• AIM IMMUNOTECH INC.: revenue
• AIM IMMUNOTECH INC.: contract revenue excluding tax
• AIM IMMUNOTECH INC.: financing cash flow
• AIM IMMUNOTECH INC.: investing cash flow
• AIM IMMUNOTECH INC.: retained earnings or deficit
• AIM IMMUNOTECH INC.: basic weighted-average shares
• AIM IMMUNOTECH INC.: diluted weighted-average shares
• AIM IMMUNOTECH INC.: basic earnings per share
• AIM IMMUNOTECH INC.: diluted earnings per share
• AIM IMMUNOTECH INC.: net property, plant and equipment
• AIM IMMUNOTECH INC.: share-based compensation expense
• AIM IMMUNOTECH INC.: operating income or loss
• AIM IMMUNOTECH INC.: current assets
• AIM IMMUNOTECH INC.: interest expense
• AIM IMMUNOTECH INC.: current liabilities
• AIM IMMUNOTECH INC.: current accounts payable
• AIM IMMUNOTECH INC.: net finite-lived intangible assets
• AIM IMMUNOTECH INC.: net current accounts receivable
• AIM IMMUNOTECH INC.: cost of revenue
• AIM IMMUNOTECH INC.: research and development expense
• AIM IMMUNOTECH INC.: common shares outstanding
• AIM IMMUNOTECH INC.: additional paid-in capital
• AIM IMMUNOTECH INC.: accumulated other comprehensive income or loss
• AIM IMMUNOTECH INC.: total equity including noncontrolling interests
• AIM IMMUNOTECH INC.: operating lease right-of-use asset
• AIM IMMUNOTECH INC.: operating lease liability
• AIM IMMUNOTECH INC.: long-term debt
• AIM IMMUNOTECH INC.: gross property, plant and equipment
• AIM IMMUNOTECH INC.: accumulated depreciation on property, plant and equipment
• AIM IMMUNOTECH INC.: other noncurrent assets
• AIM IMMUNOTECH INC.: accrued current liabilities
• AIM IMMUNOTECH INC.: prepaid expenses and other current assets
• AIM IMMUNOTECH INC.: net deferred tax assets
• AIM IMMUNOTECH INC.: profit or loss including noncontrolling interests
• AIM IMMUNOTECH INC.: comprehensive income or loss
• AIM IMMUNOTECH INC.: general and administrative expense
• AIM IMMUNOTECH INC.: depreciation expense
• AIM IMMUNOTECH INC.: amortization of intangible assets
• AIM IMMUNOTECH INC.: other nonoperating income or expense
• AIM IMMUNOTECH INC.: interest paid, net
• AIM IMMUNOTECH INC.: change in accounts receivable
• AIM IMMUNOTECH INC.: change in inventories
• AIM IMMUNOTECH INC.: change in accounts payable

Inspect the source

Entity

AIM IMMUNOTECH INC. / CIK 0000946644

Captured

2026-09-20T05:10:35.627Z

SEC response SHA-256

afa53ad5ae1b337fce564570fdcdd33eb2021618e07f9401e61eecace732bd67

Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON

Latest-filed annual-report facts per unit and reporting period at capture time. Duration facts cover 300 to 400 days. This selection can include restatements and is not a point-in-time backtest dataset. Missing concepts are omitted, never zero-filled. Values retain original units and are not currency converted. Extended concepts require compatible unit shapes and at least three reporting ends with changing values within one unit. Constant or incompatible added histories are omitted.

Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.

Use this in research

A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.

These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.

Research methodology · Execution and cost assumptions · Check backtest overfitting

Build with the open-source tools

Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.

• Get an API key and run your first validation
• Connect the MCP server to your coding assistant
• Inspect the ALPHAC engine on GitHub
• Read the MCP server source and integration examples

import json
from urllib.request import urlopen

with urlopen("https://canlicapital.com/company-data/0000946644.json") as response:
    record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
    print(concept["tag"], next(iter(concept["observations"])))